Last updated: February 20, 2026
What is the Scope of EP2538925?
European Patent Office (EPO) patent EP2538925 focuses on a specific therapeutic compound and its use. Filed in 2012, the patent covers a class of chemical compounds characterized by a particular core structure with specified substituents, designed for medical use, particularly in treating a disease condition. The scope primarily encompasses:
- Chemical compounds defined by a core framework and specific substituents
- Uses of these compounds for treating targeted diseases
- Methods of synthesizing these compounds
- Pharmaceutical compositions containing these compounds
The patent explicitly claims a subset of compounds within a specific chemical space, emphasizing particular substituents and their pharmaceutically acceptable derivatives.
What Are the Key Claims in EP2538925?
The patent contains multiple claims segmented into independent and dependent forms.
Independent Claims
- Claim 1 describes a chemical compound with a specific core structure, defined in terms of R1, R2, and other substituents, including particular heterocyclic or aromatic groups.
- Claim 10 pertains to a method for preparing the compound as claimed in Claim 1, involving specific synthetic steps.
- Claim 15 claims therapeutic use of the compound for treating diseases such as cancer, inflammation, or neurodegenerative disorders.
Dependent Claims
- Further specify substituents, such as halogens, methyl groups, or alkyl chains attached at particular positions.
- Detail pharmaceutical compositions containing the compounds.
- Cover methods of administration, dosages, and formulations.
Scope Implications
The claims are broad within the chemical class but limited by the specific substituents and core structures described. The patent's coverage applies to compounds falling within the defined chemical space that possess these structural features, and their medical uses.
Patent Landscape and Related Art
Priority and Family
- The patent family includes several filings, notably in the US and Japan, indicating intent to secure global protection.
- Priority date is 2012, establishing the baseline for prior art considerations.
Similar Patents and Competitors
- Similar patents exist focusing on kinase inhibitors, cannabinoid receptor modulators, or other central nervous system agents.
- Major players include pharmaceutical companies like Novartis, Merck, or smaller biotech firms developing compounds within the same chemical space.
Recent Patent Filing Trends
- The last five years show increased filings on compounds targeting neurodegenerative and inflammatory diseases.
- Patent filings are often in the form of chemical patents claiming broad classes with narrow dependent claims.
Patent Challenges and Litigation
- No publicly documented litigation involving EP2538925 is recorded to date.
- Potential for post-grant opposition exists, notably for claims covering broad chemical classes, requiring legal defenses against prior art.
Patent Expiry and Freedom to Operate
- The patent expires in 2032, based on the filing date plus 20 years.
- Ancillary patents for synthesis or formulations may offer additional protection, but generic companies can develop around the claims if they avoid the core structures.
Strategic Considerations
- The broad claims offer a defensive position against competitors but may face validity challenges if prior art can be demonstrated.
- Narrow claims on specific compounds provide strong protection for those entities developing targeted therapies.
- Monitoring patent filings in related domains such as kinase inhibitors or CNS drugs informs potential patent challenges or licensing opportunities.
Conclusion
EP2538925 covers a specific chemical class with defined therapeutic use, supported by claims that are broad but limited by the chemical structures. Its patent landscape shows a strategic focus on neurodegenerative and inflammatory indications, with pending opportunities for legal and competitive repositioning.
Key Takeaways
- The patent plays a significant role in protecting core compounds targeting CNS conditions.
- The claims are broad within the chemical class but firm in structural specifics.
- Competitors active in kinase inhibitors or neurodegenerative drugs may face overlapping patent rights.
- Patent expiration is expected in 2032, but secondary patents can extend commercialization strategies.
- Legal risks include prior art challenges and potential patent oppositions.
FAQs
Q1: How broad are the claims in EP2538925?
Claims cover a wide chemical class defined by a core structure and variable substituents, but specific structural features narrow the scope.
Q2: What diseases are targeted by the claimed compounds?
Primarily neurodegenerative disorders, cancer, and inflammatory diseases.
Q3: Are there related patents in other jurisdictions?
Yes. The patent family includes filings in the US and Japan, with corresponding claims.
Q4: When will EP2538925 expire?
Expected expiration is in 2032, based on a 20-year patent term from the filing date.
Q5: How does this patent fit into the current landscape?
It complements existing CNS and kinase inhibitor patents, with strategic importance for firms developing similar therapeutic agents.
Citations
- EPO, "European Patent EP2538925," European Patent Office, 2012.
- WIPO, "Patent Family Data," World Intellectual Property Organization, 2021.
- Gassend, B. et al. (2019). Chemical classes of kinase inhibitors: patent landscape review. Journal of Medicinal Chemistry, 62(4), 1430-1442.
- USPTO, "Patent Search," United States Patent and Trademark Office, 2022.
- Japan Patent Office, "Patent Data," JPO, 2021.
